Build it & they will come

Social Media, by David Hunt

Of course they will come. We’ve sweated blood, sweat & tears to establish our social media governance. We’ve aligned all our internal stakeholders, agreed our polices & opened the doors!! We’re big pharma & they’ll be delighted to talk to us!!

To launch a social campaign requires effort, ambition & conviction. Ironically, the internal campaign required to launch a social media initiative can consume the energy necessary to drive external engagement. In essence, the internal customers can take precedent over external. The product of this dilemma is often, “Where are the interactions? Where is the engagement? Where is the community?” It’s not enough to simply open your doors, you need to build an engaging presence.

Content is King, or so we are told. However, without context & relevance we are simply pushing messages via a new platform. We all see & publish countless updates that are neither liked, retweeted, repinned or shared. And they should, they’re good. However, they’re most likely not relevant to the viewer, or the viewer is not relevant to us. To overcome this, content strategy has to be more agile. It should respond to search & community trends and the evolving interests of peers – to be relevant we must be current. Beyond this, distribution should use expert community management & intuition vs. a pre-determined timeline – to be relevant timing is critical.

There are those in society who talk solely about themselves, their agenda, their opinions. They are typically tiresome & isolated, with a hint of arrogance & belief in their own self-importance. I have a community of family, friends & peers. I’m happy to respond, engage & participate in their stories – we have genuine, balanced relationships. Pharma HAS to work harder in being a member of the community. A social endeavour must have a framework to participate & build an engaging presence – to be interesting we must be interested.trapeze

Sadly not everyone likes me. Like everyone there are those whose company I enjoy, those I don’t. Online is no different. In pharma communications we need to work harder to find peers with whom we can form mutually beneficial relationships. With limited time & effort we could identify 100 new & valuable online acquaintances. We can see their bio, online footprint, sentiment & areas of interest. As we build our presence we can, we can build these relationships. Taking time to listen, engage & discuss – to deliver ROI we need to be social. 

The Pharma Obligation to Social Media

Social media debate, by David Hunt

The patient population is at our finger tips. Technology has provided a broader platform to witness their frustrations, build lasting relationships and work collaboratively to improve outcomes. The pharma industry invests billions in the development of new treatments; they are bold, courageous and imaginative in the pursuit of scientific excellence. Yet, with a few exceptions, remain anxious, nervous and paralysed in social media. The changing environment demands industry innovation and outcome based funding. If science will be at the heart of that drive, social must be the catalyst.

Fear of a brand name?
We invest millions in building a brand, yet remain terrified of its mention in public. Of course, we cannot publicly announce our treatment and associated scientific benefits, and yes we have an obligation to ensure it is not miss-represented either positively or negatively. But are we really at fault if a member of public chooses to discusses our brand in a fair, valid and experienced manner? We live in a free world, and an increasingly global community, we must engage if we have valuable information & insight. Do we not have a moral obligation to respond with valuable insight? Why would we leave Wikipedia with data we know to be inaccurate, when it’s widely considered to be the first point of reference? The vast majority of the general public are wholly unqualified to comment on disease, symptoms, side effects or treatments, but do so with the vigor of a grand-parent championing chicken soup. We have the knowledge, rigor and expertise to harness valuable patient experiences, real-life events and dialogue to support broader society.

But what if we came across an adverse event?
What if we don’t? We all have an obligation to report adverse events. Beyond the rules there is a moral obligation. Many months ago I witnessed a psychiatric nurse discussing how, with appropriate permissions, they monitored patients on twitter – AMAZING! If the NHS can find the time & resource to use social media in such a smart fashion, then big pharma must follow suit.

We’ll be accused of #badpharma and dishonesty!
That is true whether you participate or not. I’d advocate participating and whilst you would never directly challenge an individual, voicing your position to a broadly smart community can only be more positive.

peeking

The approval process takes too long.
Social media is not just publishing content. It’s about listening. It’s an opportunity to hear from patients. It’s about understanding challenges & frustrations and working to address them. That alone is worth embracing the social world. It isn’t a fad, it’s been around since society – the playing field just got bigger.

 

As I often discuss, I’m proud to work in pharma. We make a difference, and we improve outcomes. Scientists & their amazing work will be at the heart of that success, but with the necessary courage communications experts can be the key.